🇺🇸 FDA
Patent

US 9062095

Mutant double cyclized receptor peptides inhibiting β1-adrenoceptor antibodies

granted A61KA61K38/00A61P

Quick answer

US patent 9062095 (Mutant double cyclized receptor peptides inhibiting β1-adrenoceptor antibodies) held by Julius-Maximilians-Universitat Wurzburg expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
54
CPC classes
A61K, A61K38/00, A61P, A61P29/00, A61P37/06